Overall survival after PARP maintenance treatment in platinum-sensitive relapsed ovarian cancer: opposing views of the US Food and Drug Administration and European Medicines Agency

‘Regulatory harmonization’ among governmental agencies responsible for drug approvals creates a unified multinational message for the safe and effective use of medications. As such, cooperative agreements exist between the Food and Drug Administration (FDA) and the European Medicines Agency (EMA